“441” is the abbreviation for “GS441524,” a nucleoside analog of Remdesivir developed by the American pharmaceutical company Gilead Sciences.
In 2012, Dr. Pedersen, a distinguished professor at the University of California, Davis, confirmed for the first time that the FIPV virus is a mutation of the feline coronavirus (FeCV) after 50 years of research on Feline Infectious Peritonitis (FIP).
After identifying the origin of the virus, Dr. Pedersen proposed that RNA virus-targeted inhibitors used to treat human SARS and MERS might be effective in treating the deadly disease in cats—Feline Infectious Peritonitis.
Clinical Application and Patent Registration of GS441524
In 2017, Dr. Pedersen obtained the nucleoside analog of Remdesivir, GS441524, from Gilead Sciences for the treatment of Feline Infectious Peritonitis. After a 12-week treatment of 31 infected cats, 25 of them recovered.
On September 20, 2018, Gilead Sciences successfully registered the patent for GS441524. However, since the company focused its research on the Ebola virus and was committed to the commercialization of Remdesivir, and given that Gilead had no veterinary division and was not interested in manufacturing animal pharmaceuticals, it refused to submit an application for GS441524 to the FDA.
Emergence of Domestic Generic Drugs
Despite the fact that the original GS441524 has not yet been launched, its formula is publicly available, which has led to the emergence of various generic drugs in China. Regardless of the brand or manufacturer, these are all considered generic drugs.
Original article by KPTer, if reproduced, please cite the source: https://www.kaipet.com/en/441-effective-drug-feline-infectious-peritonitis
